A Randomized, Noninferiority Trial Comparing ICS thorn LABA with ICS plus LABA plus LAMA in Asthma-COPD Overlap (ACO) Treatment: The ACO Treatment with Optimal Medications (ATOMIC) Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, So-Young | - |
dc.contributor.author | Kim, Solmi | - |
dc.contributor.author | Kim, Jung-Hyun | - |
dc.contributor.author | Kim, Sae-Hoon | - |
dc.contributor.author | Lee, Taehoon | - |
dc.contributor.author | Yoon, Sun-Young | - |
dc.contributor.author | Kim, Min-Hye | - |
dc.contributor.author | Moon, Ji-Yong | - |
dc.contributor.author | Yang, Min-Suk | - |
dc.contributor.author | Jung, Jae-Woo | - |
dc.contributor.author | Kim, Joo-Hee | - |
dc.contributor.author | Choi, Jeong-Hee | - |
dc.contributor.author | Park, Chan Sun | - |
dc.contributor.author | Kim, Sujeong | - |
dc.contributor.author | Lee, Jaechun | - |
dc.contributor.author | Kwon, Jae-Woo | - |
dc.contributor.author | Hur, Gyu Young | - |
dc.contributor.author | Kim, Sang-Ha | - |
dc.contributor.author | Kim, Hee-Kyoo | - |
dc.contributor.author | Shin, Yoo Seob | - |
dc.contributor.author | Kim, Sang-Hoon | - |
dc.contributor.author | Nam, Young-Hee | - |
dc.contributor.author | Jang, An-Soo | - |
dc.contributor.author | Park, Seo Young | - |
dc.contributor.author | Kim, Tae-Bum | - |
dc.date.accessioned | 2022-11-04T21:41:57Z | - |
dc.date.available | 2022-11-04T21:41:57Z | - |
dc.date.created | 2022-11-04 | - |
dc.date.issued | 2021-03 | - |
dc.identifier.issn | 2213-2198 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/144707 | - |
dc.description.abstract | BACKGROUND: Current guidelines for the treatment of asthma and chronic obstructive pulmonary disease overlap (ACO) recommend initial treatment using inhaled corticosteroids (ICSs) plus 1 or more bronchodilators. OBJECTIVE: To clarify which therapeutic effect is better between the ICS D long-acting beta(2) agonist (LABA) and ICS D LABA D long-acting muscarinic antagonist (LAMA) treatment in patients with ACO. METHODS: We conducted a multicenter, 48-week, randomized, noninferiority trial. Patients with ACO were enrolled if they were treated with a moderate to high dose of ICS D LABA. In total, 303 patients were involved in the present trial, with 149 receiving ICS D LABA D LAMA. The primary end point was the time to first exacerbation. Secondary outcomes included changes in FEV1, forced vital capacity, FEV1/forced vital capacity ratio, asthma control, blood eosinophil count, and fractional exhaled nitric oxide. RESULTS: In the ICS D LABA treatment group, 29 of 154 patients (18.83%) experienced exacerbation, whereas 28 of 149 patients (18.79%) experienced exacerbation in the ICS D LABA D LAMA treatment group. The results of this noninferiority study were ultimately inconclusive (hazard ratio, 1.1; 95% CI, 0.66-1.84). However, the patients treated with the addition of LAMA showed significant improvements in FEV1 and forced vital capacity (P <.001). Asthma control did not improve in either group. CONCLUSIONS: Although this study was unable to conclude that ICS D LABA treatment is not inferior to ICS D LABA D LAMA in terms of exacerbation, it is obvious that the ICS D LABADLAMA treatment group had improved lung function in ACO. (C) 2020 American Academy of Allergy, Asthma & Immunology | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.title | A Randomized, Noninferiority Trial Comparing ICS thorn LABA with ICS plus LABA plus LAMA in Asthma-COPD Overlap (ACO) Treatment: The ACO Treatment with Optimal Medications (ATOMIC) Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Hur, Gyu Young | - |
dc.identifier.doi | 10.1016/j.jaip.2020.09.066 | - |
dc.identifier.scopusid | 2-s2.0-85096385681 | - |
dc.identifier.wosid | 000632634600028 | - |
dc.identifier.bibliographicCitation | JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, v.9, no.3, pp.1304 - + | - |
dc.relation.isPartOf | JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE | - |
dc.citation.title | JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE | - |
dc.citation.volume | 9 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 1304 | - |
dc.citation.endPage | + | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Allergy | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Allergy | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.subject.keywordAuthor | Asthma-COPD overlap | - |
dc.subject.keywordAuthor | ICS | - |
dc.subject.keywordAuthor | LABA | - |
dc.subject.keywordAuthor | LAMA | - |
dc.subject.keywordAuthor | Triple therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.